Ignite Creation Date:
2024-05-05 @ 9:53 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00002358
Status:
COMPLETED
Last Update Posted:
2007-10-02
First Post:
1999-11-02
Brief Title:
A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease VZV in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
Open-Label BV-araU Treatment of Pediatric HIV-Infected Patients With Cutaneous Visceral or Ocular Varicella-Zoster Viral Disease Who Have Failed or Are Intolerant of Standard Therapy
Status:
COMPLETED
Status Verified Date:
2007-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To provide oral sorivudine BV-araU to pediatric HIV-infected patients with varicella-zoster viral disease who have failed or are intolerant of alternative therapy
Detailed Description:
Any physician qualified to treat pediatric AIDS patients may enroll patients in this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| AI458-903 | None | None | None |